Primary record
2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
- 库存
- 7,971 克
- 纯度
- 99.5 %
- CAS
- 148031-34-9
化合物标识与属性
- CAS
- 148031-34-9
- PubChem CID
- 123610
- SMILES
- C1CC2C(=O)NC(CSSCCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N
- Canonical SMILES
- NC(=O)C1CSSCCC(=O)NC(CCCCN=C(N)N)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)N2CCCC2C(=O)N1
名称与同义词
- Eptifibatide
- Eptifibatide Acetate
- Integrilin
- Integrelin
- Eptifitide
- Intrifiban
- Ethoxyfen
- Integrilin (TN)
- Eptifibatide (INN)
- n-17-yl)acetic acid
- 148031-34-9
- AC1L3WYY
- Eptifibatide [INN:BAN]
- RefChem:1049322
- 188627-80-7
- SCHEMBL1649793
- SCHEMBL8284422
- C35H49N11O9S2
- UNII-NA8320J834
- CTK8F0756
- EPT-3786-PI
- DTXCID20210124
- DTXSID60861477
- HMS3743E11
- AMY25372
- BCP02070
- YFA03134
- CID123610
- MFCD05662245
- AN-5551
- Eptifibatide Acetate OAIae degrees IeA
- C35-H49-N11-O9-S2
- AN-30420
- DB-044679
- LS-182837
- RT-012487
- FT-0602106
- FT-0652986
- NS00007519
- 2-[20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
- D06888
- EN300-120649
- SBI-0654158.0001
- SR-01000942234
- I06-0351
- SR-01000942234-1
- BRD-A90547603-001-02-5
- 148031-34-9;Eptifibatide acetate; Integrilin; Integrelin
- L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-, cyclic (1->6)-disulfide
- 2-[20-carbamoyl-12-(4-guanidinobutyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
- 881997-86-0
- (11-(4-Carbamimidamidobutyl)-3-carbamoyl-20-((1H-indol-3-yl)methyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo(2,1-g)(1,2,5,8,11,14,17,20)dithiahexaazacyclotricosin-17-yl)acetic acid
- 1248559-53-6
- 2-(20-((1H-indol-3-yl)methyl)-3-carbamoyl-11-(4-((diaminomethylene)amino)butyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2]dithia[5,8,11,14,17,20]hexaazacyclotricosi
- 2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
- 2-[11-(4-carbamimidamidobutyl)-3-carbamoyl-20-[(1H-indol-3-yl)methyl]-1,9,12,15,18,21-hexaoxo-docosahydro-1H-pyrrolo[2,1-g]1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosan-17-yl]acetic acid
- L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic (1-6)-disulfide
- L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-, cyclic (1?6)-disulfide
- L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-, cyclic (16)-disulfide
- N(sup 6)-Amidino-N(sup 2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide
- N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-.alpha.-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide Cyclic (16)-Disulfide